Alnylam Pharmaceuticals Inc (NASDAQ:ALNY) currently has a daily average trading volume of 746.06K but it saw 732514 shares traded in last market. With a market cap of 34.38B USD, the company’s current market price of $266.54 came rising about 0.58 while comparing to the previous closing price of $264.99. In past 52 weeks, the stock remained buoying in the range of price level as high as $304.39 and as low as $141.98. In the recent trading on the day, stock has struck highest price mark of $262.17 while lowest mark touched by it was $269.12.
Taking a look at 20-day trading activity of Alnylam Pharmaceuticals Inc (ALNY) gives us an average price of $243.75, while its current price level is -12.43% below from 52-week high level whereas it is 87.74% above from lowest level seen by the stock during that period. Simple moving average of 50 days or SMA-50 of the stock’s closing price is $248.79 while that of 200 days or SMA-200 reads an average of $230.13. A closer look into the stock’s movement over the week reveals that its volatility is standing at 3.92% during that period while stretching the period over a month that decreases to 3.67%. It is also necessary to take a look into other indicators of a stock too, to get a better idea about its price movement. And in doing so, we find stock’s 14-day relative strength index (RSI) standing at 62.63 which implies that the stock is in neutral territory.
Goldman issued its recommendations for the stock as it upgraded the price target for the stock in the range of between $198 and $370.
Over the week, ALNY’s stock price is moving 10.82% up while it is 12.03% when we observe its performance for the past one month. Year-to-date it is 13.27% up and over the past year, the stock is showing an upside performance of 44.84%.
The company is expected to be releasing its next quarterly report in February, for which analysts forecasted an EPS of -0.14 while estimate for next year EPS is -0.18. In next quarter, company is expected to be making quarterly sales of $548.82M as analysts are expecting the sales for current fiscal year at $2.23B and seeing the company making $2.67B in sales next year. Moreover, analysts are in estimates of $579.57M for current-quarter revenue.
Currently, Alnylam Pharmaceuticals Inc’s total number of outstanding shares is 128.84M with 0.43% of that held by the insiders while 98.03% of its common stock has been owned by the institutions. Company’s return on investment (ROI) stands at -12.65%. Stock’s beta reads 0.35. Stock has a price to book (P/B) ratio of 1061.40 while price to sale or P/S ratio amounts to 16.41. Its return on asset (ROA) is -8.26% on average.
